

Spectrum of *BRCA1/2* point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families

Patricio Gonzalez-Hormazabal · Sara Gutierrez-Enriquez · Daniel Gaete · Jose M. Reyes · Octavio Peralta · Enrique Waugh · Fernando Gomez · Sonia Margarit · Teresa Bravo · Rafael Blanco · Orland Diez · Lilian Jara

Received: 13 July 2010 / Accepted: 6 September 2010 / Published online: 22 September 2010
© Springer Science+Business Media, LLC. 2010

Abstract The distribution of *BRCA1/2* germline mutations in breast/ovarian cancer (BC/OC) families varies among different populations. In the Chilean population, there are only two reports of mutation analysis of *BRCA1/2*, and these included a low number of BC and/or OC patients. Moreover, the prevalence of *BRCA1/2* genomic rearrangements in Chilean and in other South American populations is unknown. In this article, we present the mutation-detection data corresponding to a set of 326 high-risk families analyzed by conformation-sensitive gel electrophoresis and heteroduplex analysis. To determine the contribution of *BRCA1/2* LGRs in Chilean BC patients, we analyzed 56 high-risk subjects with no pathogenic *BRCA1/2* point mutations. Germline *BRCA1/2* point mutations were found in 23 (7.1%) of the 326 Chilean families. Families which had at least three BC and/or OC cases showed the highest frequency of mutations (15.9%). We identified 14 point

pathogenic mutations. Three recurrent mutations in *BRCA1* (c.187_188delAG, c.2605_2606delTT, and c.3450_3453 delCAAG) and three in *BRCA2* (c.4969_4970insTG, c.5374_5377delTATG, and c.6503_6504delTT) contributed to 63.6 and 66.7% of all the deleterious mutations of each gene, which may reflect the presence of region-specific founder effects. Taken together *BRCA1/2* recurrent point mutations account for 65.2% (15/23) of the *BRCA1/2* (+) families. No large deletions or duplications involving *BRCA1/2* were identified in a subgroup of 56 index cases negative for *BRCA1/2* point mutations. Our study, which is the largest conducted to date in a South American population, provides a comprehensive analysis on the type and distribution of *BRCA1/2* mutations and allelic variants.

Keywords Breast cancer · *BRCA1/2* · Chilean population · LGRs · Recurrent mutations

Orland Diez and Lilian Jara contributed equally to this study.

P. Gonzalez-Hormazabal · D. Gaete · R. Blanco · L. Jara (✉)
Human Genetics Program, Institute of Biomedical Sciences (ICBM), School of Medicine, University of Chile,
Av. Independencia 1027, P.O. Box 70061, Santiago, Chile
e-mail: ljara@med.uchile.cl

S. Gutierrez-Enriquez · O. Diez
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

S. Gutierrez-Enriquez
Medical Oncology Program, Vall d'Hebron University
Hospital Research Institute, Barcelona, Spain

J. M. Reyes · O. Peralta
Clínica Las Condes, Santiago, Chile

O. Peralta
Department of Gynaecology and Obstetrics, School of Medicine,
University of Chile, Av Santa Rosa 1234, Santiago, Chile

E. Waugh · F. Gomez
Clínica Santa María, Santiago, Chile

S. Margarit
School of Medicine and Clínica Alemana, Universidad
del Desarrollo, Santiago, Chile

T. Bravo
National Cancer Society (Corporación Nacional del
Cáncer—CONAC), Santiago, Chile

O. Diez (✉)
Oncogenetics Laboratory, Molecular Medicine and Genetics
Program, University Hospital Vall d'Hebron, Passeig Vall
d'Hebron 119-129, 08035 Barcelona, Spain
e-mail: odiez@vhebron.net

Introduction

Breast cancer (BC) is the most common cancer among women worldwide. It has been established that one out of eight women will develop BC during their lives [1]. In Chile, mortality in women due to BC has risen, from 8.5 deaths per 100,000 women in 1985 to 12.8 per 100,000 women in 1995 [2]. Currently, it has the second-highest mortality rate among cancers (13.8/100,000 women) [3]. Incidence increased from 16.2/100,000 women in 1998 to 26.2/100,000 women in 2002 [4].

Hereditary BC accounts for 5–15% of all the BC cases [5]. Together, germline mutations in the two major susceptibility genes *BRCA1* and *BRCA2* (*BRCA1/2*) account for approximately 20% of familial BC cases [6]. Carriers of mutations in any of these genes have a 40–85% cumulative lifetime risk of BC by the age of 70. Studies of *BRCA1/2* mutation frequencies have revealed significant differences in populations of different geographic regions and ethnicities. Disease-causing mutations are distributed throughout the entire coding regions of both genes. Since the identification of *BRCA1* and *BRCA2* as the principal genes responsible for inherited BC [7, 8], more than 3,400 distinct DNA sequence variants have been described in the BIC database (<http://research.nhgri.nih.gov/bic/>), of which 1,625 can be classified as pathogenic, including 1,454 truncating mutations (1,075 frameshift and 379 nonsense) and 139 splicing alterations. The remaining mutations, including 1,351 distinct missense changes, are unclassified variants of uncertain clinical consequences. In addition to point mutations that can be detected within a PCR fragment, *BRCA1* and *BRCA2* are both known to have germline mutations resulting from Large Genomic Rearrangements (LGRs) that result in duplications or deletions of one or more exons, usually producing premature stop codons.

Little is known about the contribution of *BRCA1/2* to hereditary BC in South American populations. In the Chilean population, there are only two reports of mutation analysis of *BRCA1/2*, and these included a low number of BC and/or ovarian cancer (OC) patients [9, 10]. Moreover, the prevalence of *BRCA1/2* genomic rearrangements in Chilean and in other South American populations is unknown. In this article, we present the mutation-detection data corresponding to a set of 326 high-risk families analyzed by conformation-sensitive gel electrophoresis and heteroduplex analysis. Results of 64 out of these 326 high-risk families were previously reported [9] showing that the *BRCA1/2* gene mutation spectrum was heterogeneous and broad. Our current study, which is the largest conducted to date in a South American population, provides a comprehensive analysis on the type and distribution of *BRCA1/2* mutations and allelic variants. To determine the contribution of *BRCA1/2* LGRs in Chilean BC patients, we

analyzed 56 high-risk subjects with no pathogenic *BRCA1/2* point mutations.

Methods

Families

In this study, 326 high-risk BC/OC Chilean families were selected from the files of the Servicio de Salud del Area Metropolitana de Santiago, Corporación Nacional del Cáncer (CONAC) and other private services in the Metropolitan Area of Santiago. Pedigrees were constructed on the basis of an index case considered to have the highest probability of being a deleterious mutation carrier. None of the families met the strict criteria for other known syndromes involving BC, such as Li-Fraumeni, ataxia-telangiectasia, or Cowden disease. All the families participating in the study self reported Chilean ancestry dating several generations, after extensive interviews with several members of each family from different generations.

Table 1 shows the specific characteristic of the families selected according to the inclusion criteria. In the sample of selected families, 15.3% (50/326) had bilateral BC, 9.0% (29/326) had BC and OC, and 2.8% (9/326) presented male BC. From the 326 families which participated in this study, 348 women had only BC, 2 had both BC and OC, 5 had OC, and 7 had male BC. BC and OC for all the cases included in the study were verified using the original pathology report.

This study was approved by the Institutional Review Board of the School of Medicine of the University of Chile. Informed consent was obtained from all the participants.

Table 1 Inclusion criteria for the families included in this study

Group	Inclusion criteria	Families N (%)
A	Three or more family members with breast and/or ovarian cancer	88 (27.0)
B	Two family members with breast cancer	106 (32.5)
C	One family member with breast cancer and one with ovarian cancer	9 (3.4)
D	Single affected individual with breast cancer \leq age 35	57 (17.5)
E	Single affected individual with breast cancer \leq age 50	60 (18.0)
F	Single affected individual with male breast cancer	6 (1.8)
Total		326 (100)

BRCA1 and *BRCA2* mutation analysis

Genomic DNA was extracted from peripheral blood lymphocytes of 362 index cases belonging to the 326 high-risk selected families. Samples were obtained according to the method described by Chomczynski and Sacchi [11].

The whole coding sequences and exon–intron boundaries of the *BRCA1* and *BRCA2* genes were analyzed for sequence variants using conformational-sensitive gel electrophoresis according to described protocols [9]. Any fragment showing a mobility shift was directly sequenced in both directions. Sequencing was performed in an ABI prism 3100 automated fluorescence-based cycle sequencer (Applied Biosystems, USA) and a rhodamine dye terminator system (Applied Biosystems, USA).

Multiplex Ligation-Dependent probe Assay (MLPA) was performed for screening LGRs in a subgroup of 56 index cases negative for *BRCA1/2* point mutations. MLPA analysis was performed according to manufacturer instructions (MRC Holland, Holland) using the SALSA MLPA Kit P002-B1 for *BRCA1* and SALSA MLPA Kit P045-B1 for *BRCA2*. The fragments obtained were analyzed by capillary electrophoresis using an ABI3130-xl Genetic Analyzer (Applied Biosystems, USA) with a 36-cm capillary array and POP-7 polymer (Applied Biosystems, USA). GeneMapper 4.0 software (Applied Biosystems, USA) was used for fragment analysis, and the results (peak size, height, and areas) were exported to an Excel data sheet to calculate the relative peak area. Normalization was achieved by dividing the intra-normalized peak area by the average intra-normalized probe ratio of all the analyzed samples in the same round of analysis.

Mutation nomenclature

Mutations are described at the cDNA level according to the Human *BRCA1* reference sequence: accession U14680 and the Human *BRCA2* reference sequence: accession U43746, from GenBank sequence database (<http://www.ncbi.nlm.nih.gov/genbank/>). The *BRCA1* and *BRCA2* numbering for the BIC traditional mutation nomenclature are based on reference sequences as stated above where the A of the ATG translation initiation codon is at position 120 of *BRCA1* and position 229 of *BRCA2*. The Human Genome Organization (HUGO) systematic nomenclature for the description of sequence variants in DNA and protein sequences [12] follows the rule in which the A of the ATG translation initiation codon is +1.

Results

The *BRCA1* and *BRCA2* genes of 362 index cases belonging to 326 high-risk unrelated families were scanned for mutations. We identified a total of 14 point pathogenic

mutations (seven in *BRCA1* and seven in *BRCA2*) (Tables 2 and 3). Furthermore, we identified 14 variants of unknown significance (six in *BRCA1* and eight in *BRCA2*) (Table 4) and 28 polymorphisms (17 in *BRCA1* and 11 in *BRCA2*) (Table 5). According to the type of mutation, small deletions leading to frameshifts were more frequent ($n = 11$), followed by splicing mutations ($n = 1$), insertions ($n = 1$), and a missense pathogenic mutation. No large deletions or duplications involving *BRCA1/2* were identified in a subgroup of 56 index cases negative for *BRCA1/2* point mutations.

BRCA1/2 pathogenic point mutations

Germline *BRCA1/2* point mutations were found in 23 (7.1%) of the 326 Chilean families (Table 6). Despite the low frequency of pathogenic point mutations detected in this series, the families that had at least three BC and/or OC cases showed the highest frequency of mutations (15.9%). The frequency was lower for families with two BC cases (6.6%), and two out of the nine families (22.2%) with one BC case and one OC case were carriers of pathogenic mutations. No *BRCA1/2* pathogenic mutations were identified in the group of 57 (17.5%) early onset BC patients (<35 years) reporting no first or second degree relatives affected with BC or OC (Table 6). It is probable that in this group BC is due to moderate or low penetrance genes and not to *BRCA1/2* mutations.

In the sample of 326 Chilean families, our group identified 14 point pathogenic mutations. Nine have been previously reported by our group [9], four by other groups, and one was a new mutation not previously described. Nevertheless, it is important to emphasize that two of the previously reported mutations c.3977_3980delTGAG (*BRCA1*) and c.8296delGT (*BRCA2*) have only two and one records in the BIC database, respectively. The frameshift c.3977_3980delTGAG was identified in a Chilean family (F203), which only presented two cases of female BC diagnosed at age 36 (index case) and at age 40 (bilateral BC). The father of the index case was diagnosed with prostate cancer at age 50 (Table 2). We obtained a DNA sample only from the index case who was carrier of the aforementioned mutation. This mutation has only two records in the BIC database, one of them in an Asian population. The c.8292delGT mutation has only one record in the BIC database. This mutation was found in family F93, a BC/OC cancer family containing two BC cases diagnosed at ages 26 (index case) and 32, and one OC at 60. We only analyzed the index case and four healthy relatives (a sister, a brother, and two cousins), and only the index case was a carrier of the c.8296delGT mutation.

Four of the 14 distinct pathogenic mutations found by our group were novel. To our knowledge, these have not

Table 2 *BRCA1* pathogenic point mutations detected in Chilean high-risk families

E/I	BIC nomenclature	Systematic nomenclature	Effect on amino acid	Mutation type	Family	Inclusion criteria	Index case status (age)	Family history of BC or OC (age)	Other cancers (age)
<i>BRCA1</i>									
E2	c.187_188delAG ^a	c.68_69delAG	p.E23fs (Stop39)	F	F4	B	BC (38)	2 BC (38, 62)	Prostate (82), uterine (50)
E2	c.187_188delAG ^a	c.68_69delAG	p.E23fs (Stop39)	F	F46	A	BC (42)	3 BC (42, 80, 70)	Colon (60); pancreatic (42, 65); Testicular (38); melanoma (54)
E5	c.300T>G ^a	c.181T>G	p.C61G	M	F13	A	BC (37)	4 BC (37, 37, 37, 50)	Lung (U); kidney (U) Bone (U); gastric (35), prostate (U)
E11	c.2605_2606delTT ^a	c.2486_2487delTT	p.F829Stop	F	F43	B	BC (45)	5 BC (45, 49, 51, 51, U) Bil	1 Uterine (U); 6 gastric (U)
E11	c.2605_2606delTT ^a	c.2486_2487delTT	p.F829Stop	F	F84	A	BC (40)	4 BC (40, 59, U, U)	2 Gastric (U, U)
E11	c.3450_3453delCAAAG ^a	c.3331_3334delCAAAG	p.Q1111fs (Stop1115)	F	F36	A	BC (27)	5 BC (27, 37, 37, 52, 79) Bil	3 uterine (U); esophagus (U)
E11	c.3450_3453delCAAAG ^a	c.3331_3334delCAAAG	p.Q1111fs (Stop1115)	F	F253	A	BC (61) (Male)	5 BC (61, 58, 57, 35, 60)	Prostate (60), pancreas (60), lymphoma (53)
E11	c.3450_3453delCAAAG ^a	c.3331_3334delCAAAG	p.Q1111fs (Stop1115)	F	F298	B	BC (35)	2 BC (35, 40)	Gastric (75), pancreas (60, U)
E11	c.3977_3980delTGAG ^b	c.3858_3861delTGAG	p.S1286fs (Stop1305)	F	F203	B	BC (36)	2 BC (36, 40) Bil	2 Gastric (43, 71), skin (49), prostate (59)
E11	c.4185_4188delCAAAG ^a	c.4066_4069delCAAAG	p.Q1356fs (Stop1364)	F	F21	A	BC (49)	3 BC (45, 47, 49)	–
I17	IVS17-1G>A ^a	c.5075-1G>A	affected splicing ? r.5194_5294del ?	S	F65	B	BC (44)	4 BC (44, 50, 60, 60) Bil	3 Gastric (36, 36, 50); 2 Lung (88, 50); liver (50) Colon (65); brain (U)

(E/I) Exon/intron number, ? probable effect, F frameshift, M missense, S splice, BC breast cancer, bil bilateral breast cancer, OC ovarian cancer, bil bilateral breast cancer, U unknown age at diagnosis

^a Reported in our previous report [9]^b Also included in BIC as 3975delAGTG

Table 3 *BRCA2* pathogenic point mutations detected in Chilean high-risk families

E/I	BIC nomenclature	Systematic nomenclature	Effect on aminoacid	Mutation type	Family	Inclusion criteria	Index case status (age)	Family history of BC or OC (age)	Other cancers (age)
<i>BRCA1</i>									
E11	c.4969_4970insTG	c.4740_4741insTG	p.S1580fs (Stop 1617)	F	F77	B	BC (34/43bil, 37)	2 BC (34/43bil, 37)	Esophagus (39); vesical (61)
E11	c.4969_4970insTG	c.4740_4741insTG	p.S1580fs (Stop 1617)	F	F325	A	BC (34)	3 BC (34, 40, 40)	Prostate (35); 3 gastric (60, 66, 71); 3 uterine (43, 45, 50)
E11	c.5374_5377delTATG	c.5146_5149delTATG	p.Y1716fs (Stop 1723)	F	F79	A	BC (27)	3 BC (27, 27, U)	Uterine (U)
E11	c.5374_5377delTATG	c.5146_5149delTATG	p.Y1716fs (Stop 1723)	F	F105	A	BC (41)	4 BC (41, 43, 45, 57)	3 Prostate (59, U, U)
E11	c.5374_5377delTATG	c.5146_5149delTATG	p.Y1716fs (Stop 1723)	F	F127	A	BC (25/32bil)	3 BC (25/32bil, 40, 50)	–
E11	c.5374_5377delTATG	c.5146_5149delTATG	p.Y1716fs (Stop 1723)	F	F281	A	BC (43)	4 BC (34, 43, 50, 64)	2 Gastric (60, 80)
E11	c.5667delT ^a	c.5439delT	p.L1813fs (Stop1814)	F	F37	A	BC (43)	3 BC (26, 43, 45)	Colon (U)
E11	c.6174delT ^a	c.5946delT	p.S1982fs (Stop 2003)	F	F46	A	BC (42)	3 BC (42, 80, 70) 3 OC (34, 41, 55)	Colon (60); pancreatic (42, 65); testicular (38); melanoma (54)
E11	c.6503_6504delTT ^a	c.6275_6276delTT	p.L2092fs (Stop 2098)	F	F39	B	BC (60)	3 BC (60, 67, 70)	Other cancer (U); myeloma (U)
E11	c.6503_6504delTT ^a	c.6275_6276delTT	p.L2092fs (Stop 2098)	F	F343	C	BC (35)	1 BC (35), 1OC (54)	–
E18	c.8296delGT	c.8068delGT	p.V2690fs (Stop 2691)	F	F93	C	BC (26)	2 BC (26, 32) 1 OC (60)	Uterine (38); lung (U)
E25	c.9490delG ^b	c.9262delG	p.A3088fs (Stop 3103)	F	F211	A	OC/BC (42/50)	1 OC/BC (42/50) 3 BC (38, 49, 67)	Prostate (59), lung (U)

E/I Exon/intron number, F frameshift, BC breast cancer, OC ovarian cancer, bil/bilateral breast cancer, U unknown age at diagnosis

^a Reported in our previous report [9]

^b Mutations neither indexed in BIC nor in reports by other authors

Table 4 *BRCA1* and *BRCA2* variants of unknown significance detected in Chilean high-risk families

E/I	BIC nomenclature	Systematic nomenclature	Effect on aminoacid	Mutation type (b)	Family	Inclusion criteria	Index case status (age)	Family history of BC or OC (age)	Other cancers (age)
<i>BRCA1</i>									
E2	c.138C>T	c.19C>T	p.R7C	M	F86	A	BC (54)	4 BC (54, 52, 55, 64)	Prostate (51)
E7	c.465G>C ^a	c.346G>C	p.E116Q	M	F16	C	BC (48)	3 BC (48, 53, U) 3 OC (70, 76, U)	Pancreatic (80); lung (66, U); Larynx (77); melanoma (72,53); bladder (50)
E11	c.3399T>A ^a	c.3280T>A	p.Y1094N	M	F65	A	BC (44)	4 BC (44, 50, 60, 60)	3 Stomach (36, 36, 50); 2 Lung (88, 50); liver (50) Colon (65); brain (U)
E11	c.3867G>A	c.3747G>A	p.E1250K	M	F14	B	Unaffected	3 BC (30, 36, 47)	Uterine (U); stomach (U)
E16	c.4861A>T ^a	c.4742A>T	p.E1581V	M	F38	A	BC (52)	3 BC (52, 55, 60)	Stomach (U); 2 lung (U)
E16	c.4864A>C ^a	c.4745A>C	p.D1582A	M	F38	A	BC (52)	3 BC (52, 55, 60)	Stomach (U); 2 lung (U)
<i>BRCA2</i>									
E4	c.568C>T ^a	c.340C>T	p.H114Y	M	F1	A	BC (47)	4 BC (47, 49, 50, 53)	Leukemia (U); ganglionar (U)
E11	c.4747_4749delATT ^b	c.4747_4749delATT	p.1583del I	D	F179	D	BC (32)	1 BC(32)	Gallblader (72), stomach (>50), Leukemia (>50), lung (>50)
E11	c.5015A>C ^a	c.4787A>C	p.N1596S	M	F16	C	BC (48)	2 BC (48, 53) 3 OC (70, 76, ?)	Lung (66); melanoma (72, 53)
E11	c.5972C>T ^a	c.5744C>T	p.T1915M	M	F40	A	BC (39)	4 BC (38, 39, 39, 40)	Gynaecological (U); stomach (U)
E11	c.6518C>T	c.6290C>T	p.T2097M	M	F145	E	BC (44, 46)	–	Uterine (50)
E18	c.8381T>C	c.8153T>C	p.I2718T	M	F231	B	BC (37)	2 BC (37, 50)	–
E18	c.8381T>C	c.8153T>C	p.I2718T	M	F239	B	BC (65)	2 BC (65, 34)	Gastric (65)
E22	c.9023A>C ^a	c.8795A>C	p.H2932P	M	F10	B	BC (60)	3 BC (46, 50, 60)	Thyroid (43)

E/I Exon/intron number, M missense, D deletion, BC breast cancer, OC ovarian cancer, U unknown age at diagnosis

^a Reported in our previous report [9]

^b Mutations neither indexed in BIC nor in reports by other authors

Table 5 *BRCA1* and *BRCA2* polymorphisms detected in Chilean high-risk families

E/I (a)	BIC nomenclature	Systematic nomenclature	Predicted effect
<i>BRCA1</i>			
I2	IVS2-69delTTTA ^a	c.-62-69delTTTA	Non coding
I7	IVS7+35del14 ^a	c.441+35del14	Non coding
I7	IVS7+49del15 ^a	c.441+49del15	Non coding
I7	IVS7+64delT ^a	c.441+64delT	Non coding
I8	IVS8-58delT	c.548-58delT	Non coding
I8	IVS8-57del7 ^a	c.442-57del7	Non coding
E11	c.2430T>C ^a	c.2311T>C	p.L771L
E11	c.3232A>C ^a	c.3113A>C	p.E1038G
E11	c.3667A>G ^a	c.3548A>G	p.K1183R
I17	IVS17-53C>T ^a	c.5075-53C>T	Non coding
I18	IVS18+66G>A ^a	c.5152+66G>A	Non coding
I20	IVS20+60ins12	c.5277+60ins12	Non coding
I20	IVS20-57A>C ^a	c.5278-57A>C	Non coding
I20	IVS20-56A>T ^a	c.5278-56A>T	Non coding
I20	IVS20-46C>G ^a	c.5278-46C>G	Non coding
I20	IVS20-45C>A ^a	c.5278-45C>A	Non coding
I20	IVS20-27insC ^a	c.5278-27insC	Non coding
<i>BRCA2</i>			
E2	c.203G>A ^a	c.-26G>A	5'UTR
E10	c.1038A>T ^a	c.810A>T	p.S270S
E11	c.2895T>C ^a	c.2667T>C	p.N889N
E11	c.3199A>G	c.2965A>G	p.N991D
E11	c.3255C>T ^a	c.3027C>T	p.F1009F
E11	c.3267A>G ^a	c.3039A>G	p.S1013S
E11	c.3624A>G ^a	c.3396A>G	p.K1132K
E11	c.5972T>C	c.5744T>C	p.M1915T
E11	c.8381C>T	c.8153C>T	p.I2718T
E22	c.9025A>C ^a	c.8797A>C	p.R2933R
E22	c.9078G>A ^a	c.8850G>A	p.K2950K

E/I Exon/Intron number

^a Reported in our previous report [9]

been reported in the BIC database or elsewhere. Three of them were reported in our previous study and to date have not been reported in other studies [c.2605_2606delTT (*BRCA1*); c.4185_4188delCAAG (*BRCA1*); and c.5667delT (*BRCA2*)] [9], and c.9490delG (*BRCA2*) is a new novel mutation. The *BRCA2* c.9490delG mutation was identified in only one BC/OC family (F211). The family presented three BC cases, two of them diagnosed under the age of 50, and one OC/BC diagnosed at age 42/50. This mutation was found in the index case (OC/BC) and in her sister affected with BC at age 38. This mutation is located in exon 25 and generates a stop at codon 3088, deleting 9% of the protein. The deleted segment includes a DNA binding domain with unique structural features for binding ssDNA and dsDNA.

Three recurrent mutations in *BRCA1* (c.187_188delAG, c.2605_2606delTT, and c.3450_3453delCAAG) and three in *BRCA2* (c.4969_4970insTG, c.5374_5377delTATG, and c.6503_6504delTT) contributed to 63.6 and 66.7% of all the deleterious mutations of each gene, which may reflect the presence of region-specific founder effects. The most frequent mutation of *BRCA1* was c.3450_3453delCAAG, found in three *BRCA1* (+) families (27.3%), whereas c.5374_5377delTATG was the most prevalent alteration in *BRCA2* (found in four families, 33.3%). Taken together, *BRCA1/2* recurrent point mutations account for 65.2% (15/23) of the *BRCA1/2* (+) families.

Variants of unknown significance

Six *BRCA1* variants of the missense type were detected in five different families (Table 4). Of these, five were described in our previous report [9]. In *BRCA2*, we found eight variants of unknown significance. Seven correspond to missense variants, some of which are described in our previous report [9]. In 12 of the 13 families, the variants of unknown significance were present in the BC cases; in only one family (F14) the variant was detected in a healthy

Table 6 Frequency of families with *BRCA1* or *BRCA2* pathogenic point mutations according to the inclusion criteria

Inclusion criteria	Tested families	No. of families with <i>BRCA1</i> point pathogenic mutations	No. of families with <i>BRCA2</i> point pathogenic mutations	No. of families with <i>BRCA1</i> or <i>BRCA2</i> point pathogenic mutations	(95% CI)
A	88	6 (6.8%)	8 (9.1%)	14 (15.9%)	(8.3–23.6)
B	106	5 (4.7%)	2 (1.9%)	7 (6.6%)	(1.3–10.1)
C	9	0	2 (22.2%)	2 (22.2%)	(0–49.4)
D	57	0	0	0	–
E	60	0	0	0	–
F	6	0	0	0	–
Total	326	11	11	23 (7.1%)	(4.3–9.8)

relative. In 9 of the 13 families, we obtained a DNA sample from healthy relatives only. In family F239, the mother with BC was a carrier of variant c.8381T>C, but her daughter who also had BC was not a carrier. The families who were carriers of variants of unknown significance did not present pathogenic mutations in the *BRCA1/2* genes. The only exception was F65, which presented the c.IVS17-1G>A mutation (*BRCA1*). In this family, it is likely that the BC was a result of the pathogenic mutation c.IVS17-1G>A. The most interesting variant is c.4747_4749del-ATT, which produces the deletion of codon 1583, and corresponds to a novel variant with no BIC records and not described by other authors to date. This variant produces the deletion of isoleucine at position 1583 of the *BRCA2* protein, which was found in a BC case diagnosed at age 32 with no family history of BC or OC, and was not detected in her healthy sister. Nevertheless, in her maternal lineage there are relatives with gallbladder cancer, early onset gastric cancer, leukemia, and lung cancer cases. We cannot exclude the possibility that this mutation could be a pathogenic point mutation.

Discussion

In this study, we conducted a screening for point mutations in the complete coding sequence of *BRCA1* and *BRCA2* genes in a group of 326 high-risk families. In addition, we analyzed LGR in both genes in a sample of 56 high-risk BC cases. Although there are some previous studies conducted in Hispanic American populations such as Mexico [13], Colombia [14], and Chile [10], this is the largest study conducted in high-risk families in Hispanic American population.

Evidences from different studies show that 3–50% of familiar BC cases are accounted for by mutations in *BRCA1/2* [15]. Prevalence of *BRCA1/2* mutations among high-risk cancer patients may vary by ethnicity and study inclusion criteria. In this study, the frequency of *BRCA1/2* point mutations in the high-risk families was low (7.1%). This percentage depends on the number of BC cancer in the family, the presence of OC, and on the presence of male BC. The highest frequency of *BRCA1/2* mutations was found in families ($n = 88$) with three or more cases of BC or OC [15.9%, 95% CI (8.3–23.6)], and 22.2% of the families ($n = 9$) with one BC and one OC were carriers of *BRCA1/2* mutations. Our results agree with those reported by other groups in Spanish and in Hispanic American populations. Diez et al. [16] reported 17% (95% CI 11.9–22.1) of *BRCA1/2* mutation in the group of families with three or more BC cases ($n = 206$). A study conducted in Chilean population by Gallardo et al. [10] reported a 25% mutation frequency in families with three or more BC

cases [5/20 (95% CI 6.0–44.0)] [14], and in Colombian population a 22.2% (95% CI 0–49.4) mutation frequency was found in families with three BC cases ($n = 9$). In Mexico, Ruiz-Flores et al. [13] reported that three of 17 [18% (95% CI 0–35.8)] site-specific BC families were carriers of *BRCA1/2* mutations.

No *BRCA1/2* pathogenic mutations were found in the group of early onset BC patients (<35 years), which suggests that this group of families are likely associated with other susceptibility genes. Previously, our group reported that in Chilean BC cases, the *RAD51*-135G>C polymorphism and the combined genotypes Thr/Met–E/G (*XRCC3*-T241M–*RAD51D*-E233G) were associated with an increased BC risk among women who (a) have a family history of BC, (b) are *BRCA1/2*-negative, and (c) were <50 years at onset. These findings also increased BC risk for BC cases diagnosed before 35 years and with no family history of BC and/or OC [17]. Also, Diez et al. [16] described low frequencies (2.6%) of *BRCA1/2* mutation for single women with BC and no family history.

We report four novel pathogenic mutations (two in *BRCA1* and two in *BRCA2*). Three of them were reported in our previous study [9], and the *BRCA2* c.9490delG mutation was described for the first time. The new mutation was found in the BC/OC index case of a family that included other three BC cases and one prostate cancer case. The mutation was found in the index case who presented OC at age 42 and BC at age 50 and in her sister affected with BC at age 38. We considered c.9490delG mutation to be a pathogenic mutation because it generates a truncated protein at codon 3088, deleting 330 aminoacids at its C terminus. The C-terminal aminoacids are critical because the nuclear localization signals (NLSs) of *BRCA2* reside within the final 156 residues of *BRCA2* [18]. The smallest known cancer-associated deletion of *BRCA2* is predicted to remove 224 aminoacids (7% of the coding sequence) from its C terminus [19]. Previous reports have indicated that all of the known disease-linked truncation of *BRCA2* is likely to be non-functional because they do not translocate to the nucleus [18]. Therefore, the c.9490delG is probably pathogenic and disease associated.

Recurrent mutations

In our first screening of *BRCA1/2* mutations in a sample of 64 high-risk BC and/or OC families from Chile, we conclude that the *BRCA* gene mutation spectrum was heterogeneous and broad [9]. This study found three recurrent mutations in *BRCA1* (c.187_188delAG, c.2605_2606delTT, and c.3450_3453delCAAG) and three in *BRCA2* (c.4969_4970insTG, c.5374_5377delTATG, and c.6503_6504delTT), which contributed to 63.6 and 66.7% of all the deleterious

mutations in each gene, respectively, which may reflect the presence of region-specific founder effects.

The contemporary Chilean population stems from the admixture of Amerindian peoples (Asians) with the Spanish settlers (European Caucasian) initiated in the 16th and 17th centuries. Later migrations (19th century) of Germans, Italians, Arabs, and Croatians have had only a minor impact on the overall population (not more than 4% of the total population) and are restricted to the specific locations of the country where they settled [20]. The relationships among ethnicity, Amerindian admixture, genetic markers, and socioeconomic strata have been extensively studied in Chile [21–23].

The most prevalent mutation in *BRCA1* was c.3450_3453delCAAG. This frameshift mutation deletes the SQ sequences known as SQ-cluster domain (SCD) that are the preferred sites of ATM phosphorylation. It also deletes the entire C-terminal region that includes two regions known as the BRCT domains. They are involved in DNA repair pathways and bind to many proteins. The c.3450_3453delCAAG mutation was detected in three unrelated families. Two of these families presented five cases of BC and the third family presented only two BC cases but with early age at diagnosis (Table 2). According to data from BIC database, this mutation has been identified in Norwegian, Australian, British, Spanish, African-American, and Colombian populations. Blesa et al. [24] detected this mutation in 2 (3.9%) out of 51 high-risk families from Eastern Spain (Valencian Community). In Colombia, the 3450_3453delCAAG mutation was the most commonly observed mutation in *BRCA1*, detected in 9.4% of the BC/OC cancer families from this country. The Chilean and Colombian populations have a high percentage of Hispanic admixtures; therefore, the presence of the c.3450_3453delCAAG in both countries could be explained by a founder effect of Spanish origin.

The 2605_2606delTT was reported first by our group in the Chilean population as a novel *BRCA1* mutation [9]. To date, we have detected this *BRCA1* frameshift mutation in two Chilean families that also included cases with early age at diagnosis (Table 2). No BIC records or other description exist for this mutation. The affected families (F43 and F84) with the c.2605_2606delTT mutation had Chilean ancestry dating to many generations ago. Therefore, this mutation could have been present in the original Amerindian population that inhabited Chile before the colonization.

The most prevalent mutation in *BRCA2* was c.5374_5377delTATG. It was found in four families. In addition, it was detected in other two Chilean families in a previous report [10], for a total of six unrelated carrier families in the Chilean population. This 4-pb deletion is also the third most frequent *BRCA2* mutation in Spain [16, 25, 26], and it was found in 6 of 59 (10.2%) families from different

geographic areas of this country. Three of these Spaniard families are from Castilla-Leon [27, 28]. Notably, the Spanish settlers that arrived in Chile in the 16th century came mainly from Central Spain, specifically from the former kingdom of Castilla-Leon. Therefore, it is possible that the high prevalence of c.5374_5377delTATG in Chilean families may be a consequence of a founder effect of Spanish origin. The *BRCA2* c.5374_5377delTATG mutation truncates the BRCA protein at codon 1732, disrupting three out of eight BRC repeats that interact with RAD51 and the entire C-terminal region. Previous reports have indicated that *BRCA2* is associated with an older age of diagnosis of BC [29]. On the contrary, in the Chilean families carriers of the c.5374_5377delTATG mutation the average age of BC onset is 42 years. Moreover, one of the positive families presents three cases with prostate cancer (Table 3).

The second recurrent mutation in *BRCA2* is a 2-bp insertion of TG in nucleotide 4969 in exon 11 (c.4969_4970insTG), and it leads to a premature termination at codon 1617. This frameshift mutation is predicted to result in a protein truncation at codon 1617, deleting 53% of the protein. This mutation was previously described by Gallardo et al. [10] in an Italian/Chilean family. We detected this point mutation in two unrelated families. The affected families (F77 and F325, Table 3) had Chilean ancestry dating from many generations ago. Both families had cases with early age at diagnosis (≤ 40 years), indicating a high penetrance of this mutation. Moreover, the family F325 presents one case of prostate cancer diagnosed at age 35. To the best of our knowledge, this mutation has not been described in other populations.

The spectrum of recurrent mutations identified in Chilean families differed completely from that of Hispanic families of predominantly Mexican origin from Southern California [30]. None of the six recurrent mutations identified in Hispanic families of predominantly Mexican origin in the USA were found in the Chilean families or in Hispanic families from Colombia [14], implying that the mutation spectra among Hispanic populations in South America and the USA may differ.

Variants of unknown significance

In our screening of the *BRCA1/2* genes, we found 14 variants of unknown significance, six in *BRCA1* and eight in *BRCA2* (Table 4). In 12 of the 13 families, the variants of unknown significance were identified exclusively in healthy relatives; therefore, it was not possible to establish whether they were associated with the cancers present in the families. Only in family F239, the proband with BC was carrier of variant c.8381T>C, but her daughter who also had BC was not a carrier. In this family, it is likely that

the variant is not the genetic cause of the BC. The most interesting variant was c.4747_4749delATT in exon 11 of BRCA2, which deletes isoleucine at position 1583 of the BRCA2 protein. The BRCA2 protein directly binds to human RAD51 through its eight BRC repeats located at the 5' region of exon 11. The number, sequence, and spacing between these motifs are conserved during vertebrate evolution, suggesting its functional relevance [31]. BRC3 and BRC4 (amino acids 1517–1551) repeats have the strongest interaction with RAD51 [32]. Pellegrini et al. [33] have solved the crystal structure of the BRC4 peptide sequence bound to the RAD51 protein. This structure demonstrates a series of hydrophobic and hydrophilic interactions involving the hairpin structure of BRC4. Contact between BRC4 and RAD51 is maintained from Leu1521 to Glu1548 of the BRC4 sequence. The c.4747_4749delATT mutation deletes a hydrophobic amino acid (isoleucine) at position 1583, near to BRC4. This mutation was found only in a BC case with no family history of BC or OC cancer but with early age at diagnosis. Considering that this mutation does not result in a protein truncation, it is not possible to classify it as pathogenic. Nevertheless, we cannot exclude the possibility that this mutation could be a pathogenic point mutation. Functional assays are necessary to determine how this mutation could affect critical BRC4 interaction sites.

Large genomic rearrangements

To determine the impact of *BRCA1/2* LGRs in Chilean population, 56 hereditary BC and/or OC Chilean families negative for small mutations were screened using the MLPA technique. This represents the first study to screen for LGRs in *BRCA1/2* in Chile and South America. No LGRs were found in either *BRCA1* or *BRCA2*. In different populations, it has been reported that LGRs in *BRCA1* account for 0–27% of all the disease-causing mutations, while LGRs in *BRCA2* are rare and play a minimal role in BC/OC [34, 35]. The variation in reported percentages may be attributable to ethnicity, inclusion criteria, or technique used for LGRs detection. In this study, the mutation analysis for LGRs in *BRCA1* and *BRCA2* was performed using MLPA, which is the most common technique for LGR detection in the BRCA genes. The literature recommends screening for LGRs in *BRCA1* in families with multiple cases of BC/OC and average age at diagnosis of 50 years or less. It is also recommended to screen for LGRs in *BRCA2* in families with at least one case of male BC. In this study, only 36 out of the 56 analyzed cases belong to families with at least three BC/OC cases, five of which have OC cases in their families.

With respect to ethnicity, *BRCA1/2* LGRs play little or no role in hereditary BC in Afrikaner [35], Finnish [36–

38], French-Canadian [39], and Iranian [40] populations. The high proportion of LGRs detected in the Hispanic population of the USA can be explained by a single founder deletion of exons 9–12 [41]. In Spain, the frequency of LGRs affecting the *BRCA1/2* genes has been estimated at around 2% in *BRCA1* and 1.5% in *BRCA2* in cases previously testing negative for *BRCA1/2* point mutations [42]. In Asian populations, LGRs account for 3% of case in Singapore [43] and 0.8% in Korea [44]. In the Chilean group screened in this study, no LGRs were found (0/56) in either *BRCA1* or *BRCA2*. It is likely that such mutations play no role in BC/OC or have a low frequency in the actual Chilean population.

Acknowledgments The authors thank the many families who participated in the research studies described in this article. We acknowledge the Breast Cancer Group of CONAC: Maria Teresa Barrios, Angelica Soto, Rossana Recabarren, and Leticia Garcia; and Lorena Seccia for her technical assistance. We also acknowledge the financial support of Vicerrectoria de Investigación y Desarrollo (VID) Universidad de Chile (ENL 10/04) and Corporación Nacional del Cáncer (CONAC). This study has been partially supported by a UICC International Cancer Technology Transfer Fellowship (ICR/08/152) and with Federal funds from the National Cancer Institute, National Institutes of Health under Contract NO2-CO-41101, and partially supported by a grant of the “Fondo de Investigación Sanitaria” from the Spanish Health Ministry: FIS 05/2181.

Conflict of interest The authors declare that they have no competing interests.

References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. *CA Cancer J Clin* 59:225–249
2. Peralta O, Jorquera A, Rencoret C, Castillo CD, Solé J, Campodónico Y (1995) Cáncer de mama: resultados del programa de pesquisa y tratamiento del Servicio de Salud Central. *Rev Chil Obstet Ginecol* 60:417–425
3. Departamento de Estadísticas e Información en Salud (2009). Mortalidad en mujeres, Chile, 2006. Ministerio de Salud de Chile. http://deis.minsal.cl/deis/salidas06/causas06.asp?temp=TODAS_EDADES_MUJ.htm. Accessed 14 May 2010
4. Prieto M (2006) Situación epidemiológica del cáncer de mama en Chile 1994–2003. *Rev Med Clin Condes* 17:142–148
5. Easton D (2002) Familial risks of breast cancer. *Breast Cancer Res* 4:179–181
6. Wooster R, Weber BL (2003) Breast and ovarian cancer. *New Engl J Med* 348:2339–2347
7. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 266:66–71
8. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D et al (1996) The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. *Nat Genet* 12:333–337
9. Jara L, Ampuero S, Santibáñez E, Seccia L, Rodríguez J, Bustamante M, Martínez V, Catenaccio A, Lay-Son G, Blanco R, Reyes J (2006) BRCA1 and BRCA2 mutations in a South American population. *Cancer Genet Cytogenet* 166:36–45

10. Gallardo M, Silva A, Rubio L, Alvarez C, Torrealba C, Salinas M, Tapia T, Faundez P, Palma L, Riccio ME, Paredes H, Rodriguez M, Cruz A, Rousseau C, King MC, Camus M, Alvarez M, Carvallo P (2006) Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations. *Breast Cancer Res Treat* 95:81–87
11. Chomczynski P, Sacchi N (2006) The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. *Nat Protoc* 1:581–585
12. den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. *Hum Mutat* 15:7–12
13. Ruiz-Flores P, Sinilnikova OM, Badzioch M, Calderon-Garciduenas AL, Chopin S, Fabrice O, Gonzalez-Guerrero JF, Szabo C, Lenoir G, Goldgar DE, Barrera-Saldana HA (2002) BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico. *Hum Mutat* 20:474–475
14. Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, Tawil M, Torregrosa L, Briceno I, Hamann U (2007) High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. *Breast Cancer Res Treat* 103:225–232
15. Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. *Nat Rev Cancer* 7:937–948
16. Diez O, Osorio A, Duran M, Martinez-Ferrandis JI, de la Hoya M, Salazar R, Vega A, Campos B, Rodriguez-Lopez R, Velasco E et al (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. *Hum Mutat* 22:301–312
17. Jara L, Dubois K, Gaete D, de Mayo T, Ratkevicius N, Bravo T, Margarit S, Blanco R, Gomez F, Waugh E et al (2010) Variants in DNA double-strand break repair genes and risk of familial breast cancer in a South American population. *Breast Cancer Res Treat* 122(3):813–822. doi:10.1007/s10549-009-0709-2
18. Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM (1999) Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. *Proc Natl Acad Sci USA* 96:13920–13925
19. Hakansson S, Johannsson O, Johannsson U, Sellberg G, Loman N, Gerdes AM, Holmberg E, Dahl N, Pandis N, Kristofferson U, Olsson H, Borg A (1997) Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. *Am J Hum Genet* 60:1068–1078
20. Cruz-Coke R (1976) Origen y evolución étnica de la población chilena. *Rev Med Chile* 101:365–368
21. Valenzuela CY, Harb Z (1977) Socioeconomic assortative mating in Santiago, Chile: as demonstrated using stochastic matrices of mother–child relationships applied to ABO blood groups. *Soc Biol* 24:225–233
22. Valenzuela CY, Acuña M, Harb Z (1987) Gradiente sociogenético en la población chilena. *Rev Med Chile* 115:295–299
23. Valenzuela CY (1988) On sociogenetic clines. *Ethol Sociobiol* 9:259–268
24. Blesa JR, Garcia JA, Ochoa E (2000) Frequency of germ-line BRCA1 mutations among Spanish families from a Mediterranean area. *Hum Mutat* 15:381–382
25. Diez O, Gutierrez-Enriquez S, Balmana J (2010) Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testing. *Fam Cancer* 9:187–191
26. Infante M, Duran M, Esteban-Cardenosa E, Miner C, Velasco E (2006) High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-Leon (central Spain). *J Hum Genet* 51:611–617
27. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop T, Kelsell D et al (1996) Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. *Am J Hum Genet* 58:271–280
28. Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA (1998) Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. *Am J Hum Genet* 63:1341–1351
29. Infante M, Duran M, Acedo A, Perez-Cabornero L, Sanz DJ, Garcia-Gonzalez M, Beristain E, Esteban-Cardenosa E, de la Hoya M, Teule A et al (2010) BRCA1 5272–1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin. *Clin Genet* 77:60–69
30. Weitzel JN, Lagos V, Blazer KR, Nelson R, Ricker C, Herzog J, McGuire C, Neuhausen S (2005) Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. *Cancer Epidemiol Biomarkers Prev* 14:1666–1671
31. Shivji MK, Venkitaraman AR (2004) DNA recombination, chromosomal stability and carcinogenesis: insights into the role of BRCA2. *DNA Repair (Amst)* 3:835–843
32. Powell SN, Willers H, Xia F (2002) BRCA2 keeps Rad51 in line. High-fidelity homologous recombination prevents breast and ovarian cancer? *Mol Cell* 10:1262–1263
33. Pellegrini L, Yu DS, Lo T, Anand S, Lee M, Blundell TL, Venkitaraman AR (2002) Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. *Nature* 420:287–293
34. Hansen TO, Jonson L, Albrechtsen A, Andersen MK, Ejlersen B, Nielsen FC (2009) Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families. *Breast Cancer Res Treat* 115:315–323
35. Sluiter MD, van Rensburg EJ (2010) Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. *Breast Cancer Res Treat*. doi: 10.1007/s10549-010-0817-z
36. Laurila E, Syrjakoski K, Holli K, Kallioniemi A, Karhu R (2005) Search for large genomic alterations of the BRCA1 gene in a Finnish population. *Cancer Genet Cytogenet* 163:57–61
37. Pylkas K, Erkkö H, Nikkila J, Solyom S, Winqvist R (2008) Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families. *BMC Cancer* 8:146
38. Lahti-Domenici J, Rapakko K, Paakkonen K, Allinen M, Nevanlinna H, Kujala M, Huusko P, Winqvist R (2001) Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families. *Cancer Genet Cytogenet* 129:120–123
39. Moisan AM, Fortin J, Dumont M, Samson C, Bessette P, Chiquette J, Laframboise R, Lepine J, Lesperance B, Pichette R et al (2006) No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families. *Genet Test* 10:104–115
40. Pietschmann A, Mehdipour P, Mehdipour P, Atri M, Hofmann W, Hosseini-Asl SS, Scherneck S, Mundlos S, Peters H (2005) Mutation analysis of BRCA1 and BRCA2 genes in Iranian high risk breast cancer families. *J Cancer Res Clin Oncol* 131:552–558
41. Weitzel JN, Lagos VI, Herzog JS, Judkins T, Hendrickson B, Ho JS, Ricker CN, Lowstuter KJ, Blazer KR, Tomlinson G, Scholl T (2007) Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. *Cancer Epidemiol Biomarkers Prev* 16:1615–1620
42. Del Valle J, Feliubadalo L, Nadal M, Teule A, Miro R, Cuesta R, Tornero E, Menendez M, Darder E, Brunet J, Capella G, Blanco

- I, Lazaro C (2009) Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes. *Breast Cancer Res Treat* 122(3):733–743. doi: [10.1007/s10549-009-0613-9](https://doi.org/10.1007/s10549-009-0613-9)
43. Lim YK, Lau PT, Ali AB, Lee SC, Wong JE, Putti TC, Sng JH (2007) Identification of novel BRCA large genomic rearrangements in Singapore Asian breast and ovarian patients with cancer. *Clin Genet* 71:331–342
44. Seong MW, Cho S, Noh DY, Han W, Kim SW, Park CM, Park HW, Kim SY, Kim JY, Park SS (2009) Comprehensive mutational analysis of BRCA1/BRCA2 for Korean breast cancer patients: evidence of a founder mutation. *Clin Genet* 76:152–160